CroiValve

CroíValve is a medical device company based in Dublin, Ireland, focused on developing innovative solutions for severe Tricuspid Regurgitation (TR), a serious heart valve disorder primarily affecting elderly patients. The company aims to create safer and less traumatic treatment options compared to existing technologies. Founded by Dr. Martin Quinn, a pioneer in transcatheter valve replacement, CroíValve combines clinical, technical, and commercial expertise to address this critical healthcare need. The flagship product, the DUO™ Tricuspid Coaptation Valve System, uniquely integrates repair and replacement techniques for TR. It features an Anchor System that is anchored within the Superior Vena Cava and a Coaptation Valve that can be adjusted during implantation. This minimally invasive system is designed to improve patient outcomes and provide a durable treatment alternative to traditional therapies. CroíValve's business model focuses on the development, commercialization, and sale of the DUO system to hospitals and healthcare providers. The company also offers education and training to support the adoption of its technology, targeting healthcare professionals involved in cardiovascular care.

• Employees 40
• Founded 2016
• Annual Revenue $15300000
• Total Funding $46192438